44 MILTON AVENUE, ALPHARETTA, GA
Investor Presentation
Dogwood Therapeutics Secures License for SP16 Cancer Pain Treatment, Investor Presentation
Reports Second Quarter 2025 Financial Results
Changes in Board, Management or Compensation
News, Material Contracts
Announces First Quarter 2025 Financial Results
Annual Report to Security Holders
Regains Nasdaq Compliance
Q2
Q1
FY 2024
Q3
FY 2023 amended
FY 2023
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Correspondence
Submission Upload